Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046240) COMPOSITIONS AND METHODS TO DETECT GLUA1 IN BRAIN AND TO IDENTIFY GLUA1-MEDIATED POST-TRAUMATIC STRESS DISORDER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046240 International Application No.: PCT/US2018/048250
Publication Date: 07.03.2019 International Filing Date: 28.08.2018
IPC:
A61K 31/13 (2006.01) ,C07C 13/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
13
Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
Applicants:
NEUROVATION LABS, INC. [US/US]; 330 East 38th Street Unit 20C New York, NY 10016, US
Inventors:
PERUSINI, Jennifer, Nicole; US
Agent:
AMOS, Brian, J.; US
MACEDO, Charles, R.; Amster, Rothstein & Ebenstein LLP 90 Park Avenue New York, NY 10016, US
Priority Data:
62/550,75028.08.2017US
Title (EN) COMPOSITIONS AND METHODS TO DETECT GLUA1 IN BRAIN AND TO IDENTIFY GLUA1-MEDIATED POST-TRAUMATIC STRESS DISORDER
(FR) COMPOSITIONS ET MÉTHODES POUR DÉTECTER GLUA1 DANS LE CERVEAU ET POUR IDENTIFIER UN TROUBLE DE STRESS POST-TRAUMATIQUE INDUIT PAR GLUA1
Abstract:
(EN) The present invention provides compositions and methods for detecting GluAl, as a subunit protein and/or as a GluAl -containing, GluA2-lacking AMPAR complex. The invention further provides composition and methods for detecting and/or diagnosing GluAl -mediated disorders, such as PTSD. The invention further relates to compositions that can be detected using radiological imaging techniques, and processes for performing such imaging techniques using the compositions, to identify elevated GluAl expression or activity in a subject.
(FR) La présente invention concerne des compositions et des méthodes de détection de GluA1, en tant que protéine de sous-unité et/ou en tant que complexe AMPAR contenant GluA1 et exempt de GluA2. L'invention concerne en outre une composition et des méthodes de détection et/ou de diagnostic de troubles médiés par GluA1, tel que le PTSD. L'invention concerne en outre des compositions qui peuvent être détectées à l'aide de techniques d'imagerie radiologique, et des procédés pour réaliser de telles techniques d'imagerie à l'aide des compositions, pour identifier une expression ou une activité de GluA1 élevée chez un sujet.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)